NAS:LGND (USA) Also trade in: Germany

Ligand Pharmaceuticals Inc

$ 114.68 0 (0%)
Volume: 255,477 Avg Vol (1m): 357,655
Market Cap $: 2.25 Bil Enterprise Value $: 1.39 Bil
P/E (TTM): 3.27 P/B: 2.26
Earnings Power Value 98.86
Net Current Asset Value 34.49
Tangible Book 35.05
Projected FCF 92.06
Median P/S Value 162.67
Graham Number 166.36
Peter Lynch Value 877.25
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 2.33
Cash-To-Debt ranked lower than
77.64% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
LGND: 2.33
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.14, Med: 0.55, Max: 10000
Current: 2.33
0.14
10000
Equity-to-Asset 0.56
Equity-to-Asset ranked lower than
82.44% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
LGND: 0.56
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.83, Med: 0.17, Max: 0.83
Current: 0.56
-0.83
0.83
Debt-to-Equity 0.60
Debt-to-Equity ranked lower than
87.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
LGND: 0.6
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -9.6, Med: 0.6, Max: 28.74
Current: 0.6
-9.6
28.74
Debt-to-EBITDA 0.62
Debt-to-EBITDA ranked lower than
72.96% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
LGND: 0.62
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -5.61, Med: 7.56, Max: 12.15
Current: 0.62
-5.61
12.15
Interest Coverage 2.61
Interest Coverage ranked lower than
88.40% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
LGND: 2.61
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 0.07, Med: 3.42, Max: 7.43
Current: 2.61
0.07
7.43
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.68
DISTRESS
GREY
SAFE
Beneish M-Score -3.55
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 29.39%
WACC 11.63%

Profitability & Growth : 9/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 58.81
Operating Margin ranked higher than
97.85% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
LGND: 58.81
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -80.58, Med: 30.95, Max: 65.11
Current: 58.81
-80.58
65.11
Net Margin % 320.12
Net Margin ranked higher than
96.34% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
LGND: 320.12
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -44.07, Med: 13.77, Max: 319.58
Current: 320.12
-44.07
319.58
ROE % 111.06
ROE ranked higher than
95.25% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
LGND: 111.06
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -3.04, Med: 29.93, Max: 582.43
Current: 111.06
-3.04
582.43
ROA % 48.42
ROA ranked higher than
93.27% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
LGND: 48.42
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -9.54, Med: 4.3, Max: 60.39
Current: 48.42
-9.54
60.39
ROC (Joel Greenblatt) % 2509.89
ROC (Joel Greenblatt) ranked higher than
97.78% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
LGND: 2509.89
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -337.96, Med: 545.84, Max: 6370.4
Current: 2509.89
-337.96
6370.4
3-Year Total Revenue Growth Rate 51.80
3-Year Revenue Growth Rate ranked higher than
80.34% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
LGND: 45.6
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -65, Med: 12.45, Max: 91
Current: 45.6
-65
91
3-Year Total EBITDA Growth Rate 99.40
3-Year EBITDA Growth Rate ranked higher than
92.02% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
LGND: 91.2
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 14.35, Max: 112.5
Current: 91.2
0
112.5
3-Year EPS w/o NRI Growth Rate -18.10
3-Year EPS w/o NRI Growth Rate ranked lower than
57.80% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
LGND: -18.1
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» LGND's 30-Y Financials

Financials (Next Earnings Date: 2019-08-06)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:LGND

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:PTLA XSWX:IDIA NAS:INSM NAS:RETA NAS:HALO TSE:4974 NAS:ICPT XBRU:TUB XSWX:GALE NAS:ARNA SHSE:603233 NAS:DNLI NAS:AKCA SZSE:300009 XKRX:086900 OSTO:VITR SHSE:600201 NAS:PTCT NYSE:EBS NAS:MRTX
Traded in other countries LGDN.Germany
Address 3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Ratios

Current vs industry vs history
PE Ratio (TTM) 3.27
PE Ratio ranked lower than
71.77% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
LGND: 3.27
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 3.02, Med: 96.47, Max: 340.53
Current: 3.27
3.02
340.53
Forward PE Ratio 18.87
Forward P/E ranked lower than
74.03% of 77 companies
in the Biotechnology industry.
Industry Max: 769.23, Med: 28.41, Min: 3.89
LGND: 18.87
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 3.27
PE without NRI ranked lower than
71.19% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
LGND: 3.27
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 3.02, Med: 94.59, Max: 385.93
Current: 3.27
3.02
385.93
Price-to-Owner-Earnings 2.54
Price-to-Owner-Earnings ranked higher than
56.55% of 145 companies
in the Biotechnology industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
LGND: 2.54
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 2.34, Med: 122.57, Max: 3471.29
Current: 2.54
2.34
3471.29
PB Ratio 2.26
PB Ratio ranked lower than
74.84% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
LGND: 2.26
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.09, Med: 17.04, Max: 174.72
Current: 2.26
2.09
174.72
PS Ratio 11.22
PS Ratio ranked lower than
64.46% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
LGND: 11.22
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 4.63, Med: 15.92, Max: 33.09
Current: 11.22
4.63
33.09
Price-to-Free-Cash-Flow 14.92
Price-to-Free-Cash-Flow ranked higher than
58.55% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
LGND: 14.92
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 13.78, Med: 58.06, Max: 305.2
Current: 14.92
13.78
305.2
Price-to-Operating-Cash-Flow 14.92
Price-to-Operating-Cash-Flow ranked higher than
50.95% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
LGND: 14.92
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 13.78, Med: 52.46, Max: 3653.33
Current: 14.92
13.78
3653.33
EV-to-EBIT 1.37
EV-to-EBIT ranked lower than
56.70% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
LGND: 1.37
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -1115.3, Med: 59.75, Max: 2345.9
Current: 1.37
-1115.3
2345.9
EV-to-EBITDA 1.35
EV-to-EBITDA ranked lower than
58.72% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
LGND: 1.35
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -113.3, Med: 56.25, Max: 155.8
Current: 1.35
-113.3
155.8
EV-to-Revenue 5.82
EV-to-Revenue ranked lower than
58.24% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
LGND: 5.82
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 2.9, Med: 16.1, Max: 34.4
Current: 5.82
2.9
34.4
PEG Ratio 0.06
PEG Ratio ranked higher than
85.22% of 115 companies
in the Biotechnology industry.
Industry Max: 99.55, Med: 2.02, Min: 0.06
LGND: 0.06
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.04, Med: 1.8, Max: 7.24
Current: 0.06
0.04
7.24
Shiller PE Ratio 22.83
Shiller PE Ratio ranked lower than
93.02% of 86 companies
in the Biotechnology industry.
Industry Max: 11472.38, Med: 42.91, Min: 0.02
LGND: 22.83
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 21.1, Med: 85.22, Max: 452.47
Current: 22.83
21.1
452.47
Current Ratio 8.39
Current Ratio ranked lower than
70.67% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
LGND: 8.39
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.28, Med: 1.75, Max: 12.94
Current: 8.39
0.28
12.94
Quick Ratio 8.33
Quick Ratio ranked lower than
67.23% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
LGND: 8.33
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.26, Med: 1.65, Max: 12.87
Current: 8.33
0.26
12.87
Days Inventory 366.40
Days Inventory ranked lower than
91.48% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
LGND: 366.4
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 33.18, Med: 107.42, Max: 331.1
Current: 366.4
33.18
331.1
Days Sales Outstanding 40.68
Days Sales Outstanding ranked lower than
51.80% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
LGND: 40.68
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 5.79, Med: 51.3, Max: 81.07
Current: 40.68
5.79
81.07
Days Payable 196.37
Days Payable ranked higher than
73.32% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
LGND: 196.37
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 153.66, Med: 254.12, Max: 822.72
Current: 196.37
153.66
822.72

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -2.10
3-Year Share Buyback Rate ranked higher than
85.76% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
LGND: -2.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -36.5, Med: -7.1, Max: 2.1
Current: -2.1
-36.5
2.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.27
Price-to-Tangible-Book ranked lower than
86.13% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
LGND: 3.27
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 3.59, Med: 18.78, Max: 206.67
Current: 3.27
3.59
206.67
Price-to-Projected-FCF 1.25
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
60.10% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
LGND: 1.25
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.37, Med: 4.13, Max: 40.37
Current: 1.25
1.37
40.37
Price-to-Median-PS-Value 0.70
Price-to-Median-PS-Value ranked lower than
68.58% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
LGND: 0.7
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.23, Med: 0.79, Max: 40.05
Current: 0.7
0.23
40.05
Price-to-Peter-Lynch-Fair-Value 0.13
Price-to-Peter-Lynch-Fair-Value ranked lower than
62.50% of 64 companies
in the Biotechnology industry.
Industry Max: 13.37, Med: 1.72, Min: 0.02
LGND: 0.13
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.14, Med: 3.12, Max: 12.78
Current: 0.13
0.14
12.78
Price-to-Graham-Number 0.69
Price-to-Graham-Number ranked lower than
80.00% of 200 companies
in the Biotechnology industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
LGND: 0.69
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 0.76, Med: 5.07, Max: 31.5
Current: 0.69
0.76
31.5
Earnings Yield (Joel Greenblatt) % 72.99
Earnings Yield (Greenblatt) ranked higher than
86.40% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
LGND: 72.99
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -58.9, Med: 0.9, Max: 72.7
Current: 72.99
-58.9
72.7
Forward Rate of Return (Yacktman) % 23.07
Forward Rate of Return ranked higher than
80.74% of 135 companies
in the Biotechnology industry.
Industry Max: 107.61, Med: 11.41, Min: -475.79
LGND: 23.07
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -50.7, Med: -5.1, Max: 23.3
Current: 23.07
-50.7
23.3

More Statistics

Revenue (TTM) (Mil) $ 238.78
EPS (TTM) $ 35.09
Beta 1.73
Volatility % 57.86
52-Week Range $ 98.56 - 278.62
Shares Outstanding (Mil) 19.6

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y